EC Healthcare (02138) has issued a profit warning, projecting an EBITDA loss of HK$80.00 million–HK$110.00 million for the financial year ended 31 March 2026 (FY2026), reversing from an EBITDA gain of HK$307.80 million in FY2025.

The anticipated swing into loss is mainly driven by non-cash items: • Goodwill and intangible-asset impairments estimated at HK$250.00 million–HK$300.00 million. • Additional impairments and fair-value losses on other receivables, property, plant and equipment, investment properties and financial assets totaling HK$120.00 million–HK$180.00 million.

Stripping out these one-off charges, adjusted EBITDA is expected to reach HK$260.00 million–HK$290.00 million, below the HK$375.20 million recorded a year earlier.

Management forecasts a loss attributable to equity holders of HK$380.00 million–HK$420.00 million, wider than the HK$167.20 million loss in FY2025.

Revenue is projected at HK$3.70 billion, down 10.60 % from HK$4.14 billion the previous year, reflecting weaker consumer spending in discretionary healthcare, aesthetic medical, beauty and wellness services, as well as the full-year impact from the disposal of certain medical assets in FY2025.

Despite the expected loss, the board states that the group’s financial position remains stable, with combined cash, bank balances, time deposits and principal-protected notes of about HK$945.00 million as at 31 March 2026.

Final audited results are scheduled for release on or before 29 June 2026; shareholders and investors are advised to exercise caution when dealing in the company’s shares.